EUVIMEDEUVIMED entdecken
Crossref

Extended single-dose toxicity study of [211At]meta-astatobenzylguanidine in normal mice in preparation for the first-in-human clinical trial of targeted alpha therapy for pheochromocytoma and paraganglioma

Taiki Joho, Songji Zhao, Ken-Ichi Nishijima, Naoyuki Ukon, Saki Shimoyama, Atsushi Yamashita, Komei Washino, Tatsuya Higashi, Masao Kobayakawa, Tohru Shiga, Kazuhiro Takahashi, Hiroshi Ito

Annals of Nuclear Medicine · 2025

DOI: 10.1007/s12149-025-02065-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Nuclear Medicine, 2025. Verfasst von Taiki Joho und 11 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, Fukushima, 960-1295, Japan. Hauptthemen laut MEDLINE: Alpha Particles, Pheochromocytoma, Paraganglioma, Adrenal Gland Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: the Fukushima reconstruction budget from the Japanese government in response to the Great East Japan Earthquake.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alpha ParticlesPheochromocytomaParagangliomaAdrenal Gland NeoplasmsAstatineGuanidinesAnimalsMiceFemaleMaleHumansMice, Inbred BALB CToxicity TestsRadiopharmaceuticals

Stichwörter der Autor:innen

AstatineClinical trialMousePheochromocytomaToxicity study

Substanzen

AstatineAstatine-211GuanidinesRadiopharmaceuticals

Autor:innen und Institutionen

  • Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, Fukushima, 960-1295, Japan.
  • Department of Radiology and Nuclear Medicine, Fukushima Medical University, Fukushima, Japan.
  • Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, Fukushima, 960-1295, Japan. zhao-s@fmu.ac.jp.
  • Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
  • National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
  • Medical Research Center, Fukushima Medical University, Fukushima, Japan.

Förderung

  • the Fukushima reconstruction budget from the Japanese government in response to the Great East Japan Earthquake

Zitieren

APA

Joho, T., Zhao, S., Nishijima, K. I., Ukon, N., Shimoyama, S., Yamashita, A., Washino, K., Higashi, T., Kobayakawa, M., Shiga, T., Takahashi, K., & Ito, H. (2025). Extended single-dose toxicity study of [211At]meta-astatobenzylguanidine in normal mice in preparation for the first-in-human clinical trial of targeted alpha therapy for pheochromocytoma and paraganglioma. Annals of Nuclear Medicine. https://doi.org/10.1007/s12149-025-02065-0

Vancouver

Joho T, Zhao S, Nishijima KI, Ukon N, Shimoyama S, Yamashita A, et al. Extended single-dose toxicity study of [211At]meta-astatobenzylguanidine in normal mice in preparation for the first-in-human clinical trial of targeted alpha therapy for pheochromocytoma and paraganglioma. Annals of Nuclear Medicine. 2025. doi:10.1007/s12149-025-02065-0

BibTeX
@article{Joho2025,
  author = {Joho, Taiki and Zhao, Songji and Nishijima, Ken-Ichi and Ukon, Naoyuki and Shimoyama, Saki and Yamashita, Atsushi and Washino, Komei and Higashi, Tatsuya and Kobayakawa, Masao and Shiga, Tohru and Takahashi, Kazuhiro and Ito, Hiroshi},
  title = {Extended single-dose toxicity study of [211At]meta-astatobenzylguanidine in normal mice in preparation for the first-in-human clinical trial of targeted alpha therapy for pheochromocytoma and paraganglioma},
  journal = {Annals of Nuclear Medicine},
  year = {2025},
  doi = {10.1007/s12149-025-02065-0}
}
Kostenlos starten →